MIDDLETON, Wis.--(BUSINESS WIRE)--Imbed Biosciences (“Imbed”), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA) has ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...